110177-05-4 Usage
Uses
Used in Pharmaceutical Research and Development:
Quinoline-2-carboximide hydrochloride is used as a chemical compound in pharmaceutical research and development for its potential therapeutic properties. It is valued for its anti-inflammatory and antiproliferative effects, which make it a promising candidate for the treatment of various diseases and conditions.
Used in Drug Development as a Scaffold:
In the pharmaceutical industry, quinoline-2-carboximide hydrochloride is utilized as a scaffold for the development of new drug candidates. Its unique chemical structure and properties allow for the design and synthesis of novel compounds with potential therapeutic applications.
Used in Anti-Inflammatory Applications:
Quinoline-2-carboximide hydrochloride is used as an anti-inflammatory agent, potentially providing relief from inflammation and associated symptoms in various conditions.
Used in Antiproliferative Applications:
quinoline-2-carboxiMidaMide hydrochloride is also used in antiproliferative applications, where it may help to inhibit the uncontrolled growth of cells, making it a candidate for the treatment of certain types of cancer.
Check Digit Verification of cas no
The CAS Registry Mumber 110177-05-4 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,1,0,1,7 and 7 respectively; the second part has 2 digits, 0 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 110177-05:
(8*1)+(7*1)+(6*0)+(5*1)+(4*7)+(3*7)+(2*0)+(1*5)=74
74 % 10 = 4
So 110177-05-4 is a valid CAS Registry Number.
110177-05-4Relevant articles and documents
Synthesis and SAR of 6-chloro-4-fluoroalkylamino-2-heteroaryl-5-(substituted)phenylpyrimidines as anti-cancer agents
Zhang, Nan,Ayral-Kaloustian, Semiramis,Nguyen, Thai,Hernandez, Richard,Lucas, Judy,Discafani, Carolyn,Beyer, Carl
experimental part, p. 111 - 118 (2011/02/25)
The synthesis and SAR of a series of 6-chloro-4-fluoroalkylamino-2-heteroaryl-5-(substituted)phenylpyrimidines as anti-cancer agents are described. This series of 2-heteroarylpyrimidines was developed by modifying a series of anti-tumor [1,2,4]triazolo[1,5-a]pyrimidines and 2-cyanoaminopyrimidines we reported earlier. For the 2-heteroaryl group, the best activity is obtained when the heteroaryl group has a nitrogen atom at the ortho-position to the pyrimidyl core. The structure-activity relationship for the rest of the molecule in this 2-heteroarylpyrimidine series mimics that of the [1,2,4]triazolo[1,5-a]pyrimidine series. Like triazolopyrimidines and 2-cyanoaminopyrimidines, the 2-heteroarylpyrimidines retain the capability to overcome multidrug resistance due to Pgp. Mechanism of action studies showed that the lead compounds behaved in the same manner as triazolopyrimidines and 2-cyanoaminopyrimidines. The lead compounds in this series are more potent than the corresponding triazolopyrimidines in vitro and in vivo. Compound 21 (PTI-868) showed tumor growth inhibition in several nude mouse xenograft models, and was selected to advance to preclinical development.
